Kevin L. Winthrop

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

M. Iademarco, T. Aksamit, B. Brown-Elliott, 2007, American journal of respiratory and critical care medicine.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

L. Saiman, I. Sermet-Gaudelus, J. Herrmann, 2015, Thorax.

The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.

Katrin Roth, Anthony De Soyza, J. Elborn, 2017, Contemporary clinical trials.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

R. Gibson, L. Saiman, P. Corris, 2015, Thorax.